Press Center

April 26, 2023

Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States
April 19, 2023

Apotex Receives FDA’s Drug Shortage Assistance Award
March 1, 2023

Apotex Corp. Issues Voluntary Nationwide Recall of Brimonidine Tartrate Ophthalmic Solution, 0.15% due to cracks that have developed in some of the units caps of the bottles
April 12, 2022

Apotex Corp. Launches Generic of Abraxane® in the United States
January 19, 2022

Apotex Corp. Launches First-to-Market Authorized Generic Version of Combigan® Ophthalmic Solution in the United States
December 7, 2021

Apotex Corp. Announces Approval and Launch of Atropine Sulfate Ophthalmic Solution USP, 1% in the United States
October 7, 2021

Product Donation Supports Clinical Study to Evaluate FDA-Approved Medications for Mild-to-Moderate COVID-19 in Outpatients
March 31, 2021

Apotex Corp. Issues Voluntary Nationwide Recall of Guanfacine Extended-Release Tablets 2mg due to trace amounts of Quetiapine Fumarate
December 2, 2020

Apotex Corp. names new President & Chief Executive Officer
June 5, 2020

Apotex Corp. Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets 500mg Due to the Detection of N-nitrosodimethylamine (NDMA)
May 27, 2020

Apotex Corp. Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets 500mg Due to the Detection of N-nitrosodimethylamine (NDMA)
May 7, 2020

Apotex Corp. Resolves US Federal Government Antitrust Investigation Regarding Generic Drug Pricing
September 25, 2019

Apotex Corp. Issues Voluntary Nationwide Recall of Ranitidine Tablets 75mg and 150mg (All pack sizes and Formats) due to the potential for Detection of an Amount of Unexpected Impurity,N-nitrosodimethylamine (NDMA) Impurity in the product